Simon Spichak

After regulatory setbacks, uniQure is expected to file for accelerated approval of its one-time gene therapy for Huntington’s later this year.

Study finds that Alzheimer’s-related brain inflammation may be linked to mutations already targeted by some cancer drugs.

In a new study, lonelier older adults performed worse on memory tests, but their memory didn’t decline any faster than less lonely people.

More than 20% of people in a ALS genetics study carried at least one known genetic risk variant, including a handful of new risk factors.

A new study found adults who received a high-dose flu vaccine had a lower risk of Alzheimer’s than those who received the standard shot.

Biocomputing is a nascent but rapidly developing field at the intersection of biology and computer science. In this News and Perspectives article, JMIR Correspondent Simon Spichak reports on its current and potential applications for health care…

After breakthroughs in blindness and rare neurological diseases, researchers are testing whether gene therapy can prevent Alzheimer’s.

Bacterial infections that require hospital treatment increase dementia risk even when accounting for other risk factors.

Imaging suggests why the ability to make inferences declines after an episode of acute stress, such as a job interview. Imaging suggests why the ability to make inferences declines after an episode of acute stress, such as a job interview.

The technique aims to improve brain waste drainage, but experts say human evidence is limited despite its rapid adoption in hundreds of Chinese hospitals.

Scientists at the tau global conference discussed the development of new biomarkers that could detect tangles in neurodegenerative diseases.

A variant in the GOLGA8A gene may explain up to 60% of cases of an aggressive subtype of frontotemporal dementia.

A new study finds that alpha-synuclein may accelerate tau buildup in women’s brains, offering new insight into disease progression.

AbbVie’s experimental dopamine agonist may ease symptoms with fewer side effects, offering a potential alternative to existing treatments.

The FDA greenlist Axsome Therapeutics’ Auvelity for Alzheimer’s agitation. In studies, the drug provided a small benefit.

A trial suggests a single infusion of stem cells may slow physical decline in older adults — scientists disagree on why, or if it works.

Despite the headlines, there’s limited evidence that using large language models – like Claude and ChatGPT – is rotting the brain. But there’s enough cause for concern.

Researchers are exploring whether GLP-1 medications used for diabetes and weight loss could treat Alzheimer’s and addiction.

While the analysis suggests no noticeable clinical benefits, many clinicians think the two approved Alzheimer’s drugs offer benefits.

A growing body of research suggests astrocytes, star-shaped brain cells once dismissed as support players, may lead the way to more precise and effective psychiatric drugs.